Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 0.71 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.71 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.71 |
| ▸ | DUOX2 | Q9NRD8 | 1/20 | 0.71 |
| ▸ | DUOX1 | Q9NRD9 | 1/20 | 0.71 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928536 | 0.87 | CYBB (0.73) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL2027831 | 0.83 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL29368383 | 0.83 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4923550 | 0.74 | CYBB (0.80) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL5264056 | 0.72 | ADORA3 (0.73) | ADORA2AADORA3 | |
| SCHEMBL4920436 | 0.72 | CYBB (0.78) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4923963 | 0.71 | ADORA3 (0.71) | ADORA2AADORA3 | |
| SCHEMBL2067469 | 0.71 | ADORA2A (1.00) | ADORA2AADORA3 | |
| SCHEMBL4920220 | 0.67 | CYBB (0.69) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4928611 | 0.66 | CYBB (0.68) | CYBBNOX5NOX4DUOX2DUOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756113-B1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1756113-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | Vasopharm Biotech GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111041-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM BIOTECH GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | CYBB 2/4885NOX5 4/4885NOX4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.